About Cryoport, Inc
Cryoport, Inc., a life sciences services company, provides temperature-controlled logistics solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoportal, a cloud-based logistics management platform that supports the management of shipments, which includes order entry, document preparation, customs documentation, courier management, real-time shipment tracking and monitoring, issue resolution, and regulatory compliance requirements; and CryoPort Express Shippers, which is used to ensure that the stability of shipped biologic commodities are maintained throughout the shipping cycle; and Cryoport Express Advanced Therapy Shippers that provides verification processes to biopharma companies. It also provides information dashboards and validation documentation for shipments through data collected by the SmartPak Condition Monitoring System; and vacuum insulated aluminum dewars and cryogenic freezers systems. In addition, the company offers biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; transportation of frozen biological specimens to and from customer locations; and management of incoming and outgoing biological specimens, as well as provides logistics support and management; and short-term logistics and engineering consulting services. It serves biopharma/pharma, animal health, and human reproductive medicine markets. The company was founded in 1999 and is headquartered in Brentwood, Tennessee. Address: 112 Westwood Place, Brentwood, TN, United States, 37027
Cryoport, Inc News and around…
Latest news about Cryoport, Inc (CYRX) common stock and company :
Robert Stefanovich, Chief Financial Officer at Cryoport (NASDAQ:CYRX), made a large buy and sell of company shares on October 14, ...
Cryoport sees its Relative Strength Rating enter the 80-plus level.
Recent breakthroughs with mRNA vaccines over the past two years have shown the enormous potential for transformative therapies. DNA sequencing took off five years ago and new applications are still being developed.
A Relative Strength Rating upgrade for Cryoport shows improving technical performance.
Richard J Berman, Director at Cryoport (NASDAQ:CYRX), made a large buy and sell of company shares on September 15, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission states that Richard J Berman purchased 25,000 Cryoport shares at prices ranging from $14.35 to $18.02 per share for a total of $398,628 on September 15. They then sold their shares on the same day in the open market. They sold at prices ranging from $62.72 to $64.55 to rais
Cryoport shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 68 to 80.
A Relative Strength Rating upgrade for Cryoport shows improving technical performance. Will it continue?
In trading on Friday, metals & mining shares were relative leaders, up on the day by about 2.6%. Leading the group were shares of Lithium Americas, up about 10.9% and shares of Ramaco Resources up about 8.9% on the day.
Despite record highs in the Nasdaq recently at the 15,000 level the biotech market seems sluggish. Speculation has ebbed. As if we need a green screen every day.
Activists report to the SEC on Robinhood Markets, Oscar Health, CryoPort, Dynavax Technologies, California Resources, and Mednax
Cryoport shows rising price performance, earning an upgrade to its IBD Relative Strength Rating
After pulling data from Benzinga Pro it seems like during Q2, CryoPort (NASDAQ:CYRX) brought in sales totaling $56.19 million. However, ...
When insiders sell shares, it indicates their concern in the company’s prospects or that they view the stock as being overpriced. ...
Cryoport Inc(NASDAQ: CYRX) andMitsubishi Logistics Corporation(MLC) entereda multi-year strategic business ...
Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a leading global provider of innovative temperature-controlled supply chain solutions to the life sciences including clinical research, pharmaceutical and cell and gene therapy markets, and Mitsubishi Logistics Corporation ("MLC"), Japan's leading pharma logistics company, today announced a multi-year strategic business alliance to create an integrated regenerative medicine supply chain partnership in Japan.
Monday the US stock market moved into further robust mode fueled by official FDA approval of the Pfizer and BioNTech COVID-19 vaccines. Will the momentum last through to Thursday when the Fed's Jackson Hole Symposium kicks off remains to be seen.
A Relative Strength Rating upgrade for Cryoport shows improving technical performance. Will it continue?
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the SPDR— S&P— Health Care Equipment ETF (XHE), we found that the implied analyst target price for the ETF based upon its underlying holdings is $152.34 per unit.
Cryoport sees its Relative Strength Rating reach the 80-plus level.
CryoPort, Inc. (CYRX) delivered earnings and revenue surprises of -23.08% and 9.69%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced financial results for the three- and six-month periods ended June 30, 2021.
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Preferred Apartment Communities Inc. (APTS), where a total volume of 2,741 contracts has been traded thus far today, a contract volume which is representative of approximately 274,100 underlying shares (given that every 1 contract represents 100 underlying shares)..
CryoPort, Inc. (CYRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced that the Company will report financial results for the second quarter ended June 30, 2021 on Thursday, August 5, 2021 after U.S. markets close.
A Relative Strength Rating upgrade for Cryoport shows improving technical performance. Will it continue?
We feel now is a pretty good time to analyse Cryoport, Inc.'s ( NASDAQ:CYRX ) business as it appears the company may be...
Cryoport (CYRX) has been struggling lately, but the selling pressure may be coming to an end soon.
Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite investors’ consensus returns have been exceptional. In the following paragraphs, we find out […]
A Relative Strength Rating upgrade for Cryoport shows improving technical performance. Will it continue?
Upgrades According to Citigroup, the prior rating for Alcoa Corp (NYSE:AA) was changed from Neutral to Buy. In the ...
Cryoport, Inc (CYRX) is a NASDAQ Common Stock listed in Common Stock, Industrials, Integrated Freight & Logistics
